Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Replicate will receive research funding and could potentially receive up to approximately US$550 million
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Subscribe To Our Newsletter & Stay Updated